Durect Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
20,589.00
32,696.00
29,040.00
25,004.00
36,759.00
34,315
Total Accounts Receivable
2,349.00
2,122.00
2,222.00
1,154.00
2,376.00
1,757
Inventories
3,502.00
3,642.00
3,917.00
3,782.00
3,163.00
3,421
Other Current Assets
1,888.00
1,034.00
3,142.00
2,486.00
3,060.00
2,247
Total Current Assets
28,328.00
39,494.00
38,321.00
32,426.00
45,358.00
41,740
Net Property, Plant & Equipment
1,985.00
1,749.00
1,566.00
1,297.00
929.00
605
Total Investments and Advances
3,802.00
2,154.00
250.00
150.00
150.00
150
Intangible Assets
6,417.00
6,399.00
6,399.00
6,399.00
6,399.00
6,399
Other Assets
288.00
288.00
236.00
236.00
277.00
1,105
Total Assets
40,820.00
50,084.00
46,772.00
40,508.00
53,113.00
49,999
ST Debt & Current Portion LT Debt
-
-
-
19,853.00
7,281.00
Accounts Payable
736.00
1,021.00
1,286.00
2,086.00
1,520.00
Other Current Liabilities
6,449.00
5,947.00
6,161.00
6,811.00
7,027.00
Total Current Liabilities
7,185.00
6,968.00
7,447.00
28,750.00
15,828.00
Long-Term Debt
-
19,824.00
19,684.00
-
12,634.00
Provision for Risks & Charges
-
650.00
669.50
690.00
611.00
Other Liabilities
2,914.00
4,127.00
4,088.50
2,730.00
2,552.00
Total Liabilities
10,099.00
31,569.00
31,889.00
32,170.00
31,625.00
Common Equity (Total)
30,721.00
18,515.00
14,883.00
8,338.00
21,488.00
Total Shareholders' Equity
30,721.00
18,515.00
14,883.00
8,338.00
21,488.00
Total Equity
30,721.00
18,515.00
14,883.00
8,338.00
21,488.00
Liabilities & Shareholders' Equity
40,820.00
50,084.00
46,772.00
40,508.00
53,113.00

About Durect

View Profile
Address
10260 Bubb Road
Cupertino California 95014
United States
Employees -
Website http://www.durect.com
Updated 07/08/2019
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. Its product pipeline consists of multiple investigational drug candidates in clinical development. It offers DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery; and REMOXY ER, which provides investigational extended release pain relief.